{"analyses":[{"ciLowerLimit":"1.802","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"4.415","groupDescription":"All analyses based on final DBL were descriptive only with p-values reported as nominal.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Odds Ratio (OR)","paramValue":"2.820","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.0","upperLimit":"49.3","value":"43.6"},{"groupId":"OG001","lowerLimit":"15.8","upperLimit":"29.5","value":"22.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"312"},{"groupId":"OG001","value":"154"}],"units":"Participants"}],"description":"ORR as assessed by IRC per RECIST 1.1 was defined as the percentage of participants with a BOR of confirmed CR or PR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received cemiplimab plus platinum-based doublet chemotherapy","id":"OG000","title":"Part 2: Cemiplimab + Chemotherapy"},{"description":"Placebo matching cemiplimab plus platinum-based doublet chemotherapy","id":"OG001","title":"Part 2: Placebo + Chemotherapy"}],"paramType":"NUMBER","populationDescription":"Part 2 participants only","reportingStatus":"POSTED","timeFrame":"Up to 32 months","title":"Part 2: ORR Per IRC","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}